Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers
暂无分享,去创建一个
[1] L. Pachman,et al. Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive , 2021, bioRxiv.
[2] Z. Amoura,et al. Elevated Neopterin Levels Predict Fatal Outcome in SARS-CoV-2-Infected Patients , 2021, Frontiers in Cellular and Infection Microbiology.
[3] L. Pachman,et al. Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy , 2021, Current Treatment Options in Rheumatology.
[4] Victoria Liu,et al. Association of p155/140 Autoantibody With Loss of Nailfold Capillaries but not Generalized Lipodystrophy: A Study of Ninety‐Six Children With Juvenile Dermatomyositis , 2020, Arthritis care & research.
[5] D. Cuadras,et al. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases , 2020, Scientific Reports.
[6] Y. Hathout,et al. Serum protein biomarkers for juvenile dermatomyositis: a pilot study , 2020, BMC Rheumatology.
[7] S. Kamphuis,et al. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis , 2020, Arthritis & Rheumatology (Hoboken, N.j.).
[8] Guochun Wang,et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis , 2019, Clinical and experimental immunology.
[9] M. Viljoen,et al. Comparison between plasma neopterin and the urine neopterin:creatinine ratio as inflammatory biomarkers , 2019, African health sciences.
[10] K. Ohmura,et al. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis , 2019, Modern rheumatology.
[11] E. Hoffman,et al. Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis , 2018, Steroids.
[12] L. Pachman,et al. Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. , 2018, The Journal of pediatrics.
[13] I. Lundberg,et al. New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter , 2018, Current Rheumatology Reports.
[14] G. Shaddick,et al. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort , 2017, Journal of autoimmunity.
[15] P. Szcześniak,et al. Neopterin as a marker of cellular immunological response. , 2017, Postepy higieny i medycyny doswiadczalnej.
[16] L. Pachman,et al. Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity , 2017, RMD Open.
[17] Chiang-Ching Huang,et al. Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children , 2013, Arthritis care & research.
[18] L. Pachman,et al. Serum Neopterin Levels as a Diagnostic Marker of Hemophagocytic Lymphohistiocytosis Syndrome , 2011, Clinical and Vaccine Immunology.
[19] L. Pachman,et al. Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. , 2010, Arthritis and rheumatism.
[20] A. Vallejo,et al. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. , 2009, Arthritis and rheumatism.
[21] J. Fahey,et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] A. Dyer,et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. , 2004, The Journal of rheumatology.
[23] A. Dyer,et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. , 2003, Arthritis and rheumatism.
[24] T. Takken,et al. The physiological and physical determinants of functional ability measures in children with juvenile dermatomyositis. , 2003, Rheumatology.
[25] R. Bode,et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. , 2003, Arthritis and rheumatism.
[26] Christine A. Biron,et al. Coordinated and Distinct Roles for IFN-αβ, IL-12, and IL-15 Regulation of NK Cell Responses to Viral Infection1 , 2002, The Journal of Immunology.
[27] P. Lachenbruch,et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. , 2002, Clinical chemistry.
[28] L. Pachman,et al. Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis : Association with the TNFα-308A allele , 2001 .
[29] L. Pachman,et al. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. , 2001, Clinical immunology.
[30] David E. Levy,et al. Distinct Requirements for IFNs and STAT1 in NK Cell Function1 , 2000, The Journal of Immunology.
[31] L. Pachman,et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. , 2000, Arthritis and rheumatism.
[32] C. Heusser,et al. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells , 1993, The Journal of experimental medicine.
[33] A. Martini,et al. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. , 1993, Archives of disease in childhood.
[34] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.
[35] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975 .